XOMA - XOMA Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
24.03
-1.02 (-4.07%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close25.05
Open25.09
Bid15.15 x 100
Ask28.36 x 200
Day's Range23.90 - 25.18
52 Week Range6.86 - 37.25
Volume64,937
Avg. Volume121,485
Market Cap201.351M
Beta3.00
PE Ratio (TTM)10.93
EPS (TTM)2.20
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.00
Trade prices are not sourced from all markets
  • GlobeNewswire26 days ago

    XOMA Added to the Russell 2000® and Russell 3000® Indexes

    XOMA Corporation (XOMA), a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced the Company has been added to the Russell 2000® and Russell 3000® Indexes following the annual reconstitution, which took effect after the U.S. market closed on June 22, 2018. “We believe XOMA’s addition to these Russell indexes will enhance our visibility in the investment community and broaden our shareholder base,” stated Jim Neal, Chief Executive Officer at XOMA. The Russell 3000® Index is a market capitalization-weighted equity index that tracks the performance of the largest 3,000 U.S. stocks.

  • GlobeNewswire2 months ago

    XOMA to Present at the UBS Global Healthcare Conference

    XOMA Corporation (XOMA), a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced that Jim Neal, Chief Executive Officer, will present the Company’s royalty-aggregator business model at the UBS Global Healthcare Conference on Tuesday, May 22, 2018, at 1:00 p.m. ET. A live audio webcast of the presentation can be accessed in the Investors section of XOMA's website at www.xoma.com. XOMA has built a portfolio of over two dozen products that are licensed to and being developed by other biotech and pharmaceutical companies.

  • Associated Press2 months ago

    Xoma: 1Q Earnings Snapshot

    The Berkeley, California-based company said it had a loss of 46 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire2 months ago

    XOMA Reports First Quarter 2018 Financial Results

    EMERYVILLE, Calif., May 09, 2018-- XOMA Corporation, a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced its first quarter 2018 financial results.. “Our efforts ...

  • GlobeNewswire2 months ago

    XOMA Announces $20 Million Credit Facility with Silicon Valley Bank to Advance Royalty-Aggregator Business Model

    XOMA Corporation (XOMA), a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced it has entered into a flexible $20 million credit facility with Silicon Valley Bank, with availability through March 2019. “This credit facility gives us the option to access capital quickly as needed to capitalize on opportunities to expand our portfolio of partner-funded programs. Should XOMA draw advances from the credit facility, it will pay a floating per annum interest rate equal to the greater of (i) 4.75% and (ii) the Wall Street Journal Prime Rate plus 0.25%.

  • GlobeNewswire3 months ago

    New Research: Key Drivers of Growth for HTG Molecular Diagnostics, Impinj, XOMA, Stock Yards, TriCo Bancshares, and Alleghany — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, May 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of HTG ...

  • Associated Press5 months ago

    Xoma reports 4Q loss

    The Berkeley, California-based company said it had a loss of 16 cents per share. The drug developer posted revenue of $5.4 million in the period. For the year, the company reported net income of $14.6 ...

  • AbbVie Presents New Data on Upadacitinib for Crohn's Disease
    Zacks5 months ago

    AbbVie Presents New Data on Upadacitinib for Crohn's Disease

    AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.

  • FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
    Zacks5 months ago

    FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review

    FDA accepts Agios' NDA for its pipeline candidate ivosidenib (AG-120) and sets an action date of Aug 21, 2018.

  • AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda
    Zacks5 months ago

    AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda

    AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).

  • Theravance, J&J Ink Deal for Inflammatory Intestinal Drug
    Zacks5 months ago

    Theravance, J&J Ink Deal for Inflammatory Intestinal Drug

    Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.

  • Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down
    Zacks5 months ago

    Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down

    Keryx (KERX) reports wider-than-expected loss in Q4. However, sales surpassed estimates.

  • Pfizer Files for Xtandi in Early Stage Prostate Cancer
    Zacks5 months ago

    Pfizer Files for Xtandi in Early Stage Prostate Cancer

    Pfizer (PFE) announces detailed results from a late-stage study which can expand the label of Xtandi to include early-stage patients. It also files for approval in U.S. and EU.

  • Puma, CANbridge Team Up to Commercialize Nerlynx in China
    Zacks6 months ago

    Puma, CANbridge Team Up to Commercialize Nerlynx in China

    Puma (PBYI) enters an exclusive agreement with CANbridge under which the latter will seek regulatory approval for Nerlynx in China and develop and commercialize it in the region.

  • Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review
    Zacks6 months ago

    Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review

    Alnylam's NDA for lead candidate patisiran is accepted by the FDA and granted priority review. The FDA also set an action date of Aug 11, 2018.

  • Puma & Medison Team Up to Commercialize Nerlynx in Israel
    Zacks6 months ago

    Puma & Medison Team Up to Commercialize Nerlynx in Israel

    Puma (PBYI) and Medison enters into a licensing deal to commercialize Puma's breast cancer treatment drug Nerlynx in Israel.

  • Theravance's NDA for COPD Candidate Gets FDA Acceptance
    Zacks6 months ago

    Theravance's NDA for COPD Candidate Gets FDA Acceptance

    The FDA accepts the new drug application for Theravance (TBPH) and partner Mylan's COPD candidate, revefenacin. A response on the same is expected on Nov 13, 2018.

  • Glaxo's Shingles Vaccine Shingrix Gets Positive CHMP Opinion
    Zacks6 months ago

    Glaxo's Shingles Vaccine Shingrix Gets Positive CHMP Opinion

    The Committee for Medicinal Products for Human Use passes a positive viewpoint on Glaxo's (GSK) shingles vaccine, Shingrix. A final decision from the EU is awaited in April 2018.

  • American City Business Journals6 months ago

    East Bay drug maker soars 700 percent on Wall Street with plan to NOT make drugs

    Long considered one of biotech's walking dead, drug developer Xoma Corp. is coming alive — but not by making drugs. Xoma essentially is transforming itself from a drug-development company to a financing company, leveraging its scientific hits, cutting its costs and shedding its strategic missteps. In the end, company leaders believe, the new Xoma will leave costly and time-consuming drug development to its partners, sit back and reap the financial rewards.

  • Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y
    Zacks6 months ago

    Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y

    Dr. Reddy's (RDY) earnings per American Depositary Share were down 27.3% in third-quarter fiscal 2018 from the year-ago quarter while the top line beat the prior-year figure.

  • Shire Gets FDA Nod for Cinryze Tech Transfer to New Site
    Zacks6 months ago

    Shire Gets FDA Nod for Cinryze Tech Transfer to New Site

    Shire (SHPG) receives an FDA approval for transferring the product manufacturing technology of its hereditary angioedema drug, Cinryze, to its manufacturing site in Vienna, Austria.